about
Current Trends of Renal Impairment in Multiple MyelomaBortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathyEarly reduction of serum-free light chains associates with renal recovery in myeloma kidney.European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial.Novel approaches for reducing free light chains in patients with myeloma kidney.Achieving an early myeloma response in patients with kidney impairment.How I treat monoclonal gammopathy of renal significance (MGRS).Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival.Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.A multi-laboratory characterization of the KIR genotypes of 10th International Histocompatibility Workshop cell lines.Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report.A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.Successful use of Campath-1H in the treatment of steroid refractory liver GvHD.A case of POEMS mimicking a "Guillain-Barré like" syndrome.Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.Single nucleotide polymorphism analysis of the NKG2D ligand cluster on the long arm of chromosome 6: Extensive polymorphisms and evidence of diversity between human populations.A population-based study of the impact of dialysis on mortality in multiple myeloma.The distribution of 13 killer-cell immunoglobulin-like receptor loci in UK blood donors from three ethnic groups.Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.Donor HLA-C Genotype Has a Profound Impact on the Clinical Outcome Following Liver TransplantationAggregated serum free light chains may prevent adequate removal by high cut-off haemodialysisDifferential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidneyAn unusually late complication of central venous cannulationUsed leucodepletion filters as a source of large quantities of DNA suitable for the study of genetic variations in human populationsNon-Hodgkin's lymphoma: an unusual complication of idiopathic CD4+ lymphopeniaThe impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemiaSuccessful allogeneic haematopoietic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infectionDonor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantationIncreased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantationEthnic variability in human leukocyte antigen-E haplotypesAssociation of killer cell immunoglobulin-like receptors with primary Sjogren's syndromeMicrobiological comparison of a silver-coated and a non-coated needleless intravascular connector in clinical use
P50
Q26740444-3A572137-F579-43E3-8F90-CB50933E73F7Q33383056-E234A0FB-3CAD-4DF5-8E86-2C7DCC829C6FQ33886217-093E6E0D-D174-4728-BFDF-583679B50410Q34095668-F3100D0B-DD50-46FF-8956-75DC2BE8CD9DQ34370957-D41E888E-D0C0-4A59-AC5E-08895E0AA518Q35012436-64F2B33A-2A48-416F-A1D2-EF7C6B8DF540Q36930970-9B053F1E-C959-4EAC-AAC0-C72916B5686CQ37986358-FAE309AC-9096-403E-8A56-2FF15DA7F599Q38037708-22FCA6DE-E4F2-48F5-992D-410FF685E0A7Q38151021-FF2B2D19-C7F4-4345-98EA-2DA4E71C20CAQ38707697-737468C2-1BCC-47BE-9F12-449C3AA8AB7BQ38976968-25441163-3CD1-408C-9E06-A3ADFFB3F801Q40165373-753B7EDD-8BCF-4E7E-998F-24163F5CAA2CQ40656079-2EEF754E-320B-4A09-8D0A-37A8B3626BB3Q41044036-75DE6DCE-0710-4F60-8226-101A4595D173Q41113942-37E0924D-042D-4969-9176-5B863BAC1CF3Q43194649-7B8AA0D0-8757-41CA-9E61-181690EFDB49Q43887370-9139E6FA-F282-45D2-97F7-4342570B0674Q47413421-58E067DA-C917-44C1-BE44-DB165C65A5D1Q48500859-377C9213-EF9B-48D5-8E15-55BD010214AEQ49908392-AA48D7A1-1A16-4418-AE4C-E715A857ED99Q52838715-C515B24C-8FDA-4519-AB58-E2F4CBC8EAE3Q54437655-F0BEE89E-9E28-41AD-A73C-5A38550DE56BQ54504431-26EECEF9-C153-4DC7-8D40-B08A057D9524Q54769622-6BAD53D9-3529-4F9A-9FDE-3D07434686ACQ55042951-49174EFB-23F1-4CFC-BB13-0925D1ABBEB0Q55055579-6C3B438C-8741-4092-80F6-2584ECC48047Q61796622-6FA04C96-EA0A-4F5E-BF91-C95616A523A4Q61863486-C069AD38-B683-4BC2-B9C2-21AA5946CC15Q61863497-9EF9DEBE-FB5E-4BB6-B34E-6E344D68400BQ72011864-38ABB1DC-4792-492E-A681-6748339E3491Q73268431-75135E8D-0F79-4C06-9677-C96EED872EB4Q77498308-3D1AC6DD-052E-4BBB-9DB8-FE0BE320DF41Q79077290-E24D326D-F767-4B40-92B2-5D2CECA030ACQ80552096-F9D5F131-5820-44E8-8F44-D0EA85F99992Q81380531-138C5493-92D9-49F3-8340-AC3E266D841FQ82275287-AE006E63-DD46-4D60-A47E-D5096B13C17DQ83180823-F710320D-A2CF-491D-B97F-68994A31B777Q83269436-80DA11EC-988D-4EF9-961C-CCD3B31E884DQ83461732-DAAAC629-37DF-44EF-BCAC-ABB0C5D58375
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mark Cook
@ast
Mark Cook
@en
Mark Cook
@es
Mark Cook
@nl
Mark Cook
@sl
مارك كوك
@ar
type
label
Mark Cook
@ast
Mark Cook
@en
Mark Cook
@es
Mark Cook
@nl
Mark Cook
@sl
مارك كوك
@ar
prefLabel
Mark Cook
@ast
Mark Cook
@en
Mark Cook
@es
Mark Cook
@nl
Mark Cook
@sl
مارك كوك
@ar
P106
P21
P31
P496
0000-0001-8647-9208